BACKGROUND: Constitutive activation of signal transducer and activator of transcription-3 (STAT3) was detected in blasts from approximately 50% of patients with acute myeloid leukemia (AML) and was correlated with an adverse outcome. In vitro treatment of AML blasts with arsenic trioxide (ATO) down-regulated STAT3 activity within 6 hours associated with a reduced viability within 48 hours. METHODS: A phase 1 clinical trial to evaluate the biologically effective dose and/or the maximally tolerated dose (MTD) of ATO in vivo in conjunction with high-dose cytarabine (Hidac) and idarubicin (Ida) in patients with AML aged <60 years was conducted. Data were compared with 117 historic AML patients who had received treatment with Hidac/Ida. RESULTS: In total, 61 patients were enrolled onto 11 different dose levels (from 0.01 to 0.65 mg/kg ideal body weight). The MTD was 0.5 mg/kg. Compared with historic controls, patients who received ATO/Hidac/Ida, although they had similar pretreatment characteristics, had better overall survival (P = .039). CONCLUSIONS: ATO priming may have improved the outcome of patients aged <60 years with AML who received Hidac/Ida. The current data suggested that ATO may enhance the effect of chemotherapy. The authors concluded that further studies of this novel combination are warranted.
BACKGROUND: Constitutive activation of signal transducer and activator of transcription-3 (STAT3) was detected in blasts from approximately 50% of patients with acute myeloid leukemia (AML) and was correlated with an adverse outcome. In vitro treatment of AML blasts with arsenic trioxide (ATO) down-regulated STAT3 activity within 6 hours associated with a reduced viability within 48 hours. METHODS: A phase 1 clinical trial to evaluate the biologically effective dose and/or the maximally tolerated dose (MTD) of ATO in vivo in conjunction with high-dose cytarabine (Hidac) and idarubicin (Ida) in patients with AML aged <60 years was conducted. Data were compared with 117 historic AMLpatients who had received treatment with Hidac/Ida. RESULTS: In total, 61 patients were enrolled onto 11 different dose levels (from 0.01 to 0.65 mg/kg ideal body weight). The MTD was 0.5 mg/kg. Compared with historic controls, patients who received ATO/Hidac/Ida, although they had similar pretreatment characteristics, had better overall survival (P = .039). CONCLUSIONS:ATO priming may have improved the outcome of patients aged <60 years with AML who received Hidac/Ida. The current data suggested that ATO may enhance the effect of chemotherapy. The authors concluded that further studies of this novel combination are warranted.
Authors: Mustafa Benekli; Zheng Xia; Kathleen A Donohue; Laurie A Ford; Lynda A Pixley; Maria R Baer; Heinz Baumann; Meir Wetzler Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: Kristin E Porter; Anamika Basu; Alan E Hubbard; Michael N Bates; David Kalman; Omar Rey; Allan Smith; Martyn T Smith; Craig Steinmaus; Christine F Skibola Journal: Environ Res Date: 2010-06-01 Impact factor: 6.498
Authors: Z X Shen; G Q Chen; J H Ni; X S Li; S M Xiong; Q Y Qiu; J Zhu; W Tang; G L Sun; K Q Yang; Y Chen; L Zhou; Z W Fang; Y T Wang; J Ma; P Zhang; T D Zhang; S J Chen; Z Chen; Z Y Wang Journal: Blood Date: 1997-05-01 Impact factor: 22.113
Authors: Lorraine L Marnell; Gonzalo G Garcia-Vargas; Uttam K Chowdhury; Robert A Zakharyan; Bruce Walsh; Mihaela D Avram; Michael J Kopplin; Mariano E Cebrián; Ellen K Silbergeld; H Vasken Aposhian Journal: Chem Res Toxicol Date: 2003-12 Impact factor: 3.739
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Simrit Parmar; Lynn M Rundhaugen; Larry Boehlke; MaryBeth Riley; Chadi Nabhan; Adekunle Raji; John L Frater; Martin S Tallman Journal: Leuk Res Date: 2004-09 Impact factor: 3.156
Authors: John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: Alan K Burnett; Robert K Hills; Donald W Milligan; Anthony H Goldstone; Archibald G Prentice; Mary-Frances McMullin; Andrew Duncombe; Brenda Gibson; Keith Wheatley Journal: J Clin Oncol Date: 2009-12-28 Impact factor: 44.544
Authors: George L Chen; Hong Liu; Yali Zhang; Julie Thomas; Maureen Ross; Eunice S Wang; AnneMarie W Block; Sheila Sait; George Deeb; Paul Wallace; Meir Wetzler; Theresa Hahn; Philip L McCarthy Journal: Biol Blood Marrow Transplant Date: 2014-05-24 Impact factor: 5.742
Authors: Ashkan Emadi; Mariola Sadowska; Brandon Carter-Cooper; Vishal Bhatnagar; Isabella van der Merwe; Mark J Levis; Edward A Sausville; Rena G Lapidus Journal: Leuk Res Date: 2015-04-30 Impact factor: 3.156
Authors: Elden P Swindell; Patrick L Hankins; Haimei Chen; Denana U Miodragović; Thomas V O'Halloran Journal: Inorg Chem Date: 2013-10-22 Impact factor: 5.165
Authors: Maciej Kaźmierczak; Magdalena Luczak; Krzysztof Lewandowski; Luiza Handschuh; Anna Czyż; Małgorzata Jarmuż; Michał Gniot; Michał Michalak; Marek Figlerowicz; Mieczysław Komarnicki Journal: Med Oncol Date: 2013-10-02 Impact factor: 3.064
Authors: M Valenzuela; C Glorieux; J Stockis; B Sid; J M Sandoval; K B Felipe; M R Kviecinski; J Verrax; P Buc Calderon Journal: Br J Cancer Date: 2014-07-08 Impact factor: 7.640